Physician profile
John J Mahon
NPI 1154344752
$4,827.87
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $684 · 2021: $793 · 2022: $1,028 · 2023: $1,155 · 2024: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,563.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $990.53 | 2021-2024 | |
| Pfizer INC. | $536.93 | 2019-2024 | |
| Novo Nordisk INC | $514.74 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $449.08 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $255.70 | 2019-2023 | Evenity, Prolia |
| Janssen Pharmaceuticals, INC | $252.77 | 2019-2023 | Spravato, Xarelto |
| Watermark Medical, INC. | $247.19 | 2020 | |
| Abbott Laboratories | $190.94 | 2021-2024 | Proclaim, Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $164.58 | 2019-2024 | Farxiga, Breztri |
| Amarin Pharma, INC. | $146.54 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.64 | 2019-2024 | Xifaxan |
| Boston Scientific Corporation | $111.95 | 2019-2024 | Watchman Access System, Watchman Flx |
| Glaxosmithkline, LLC. | $99.21 | 2020-2023 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $84.00 | 2019-2023 | Steglatro, Belsomra |
| Currax Pharmaceuticals LLC | $77.89 | 2020-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.44 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $68.38 | 2022 | |
| Nevro Corp. | $67.61 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $55.34 | 2019-2021 | |
| Allergan, INC. | $55.24 | 2019-2021 | |
| Radius Health, INC. | $54.46 | 2023 | Tymlos |
| Sumitomo Pharma America, INC. | $45.26 | 2023 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $29.45 | 2021-2022 | |
| Foundation Medicine, INC. | $26.92 | 2019 | |
| Irhythm Technologies, INC. | $25.08 | 2024 | Zio Xt Patch, Zio Monitor |
| Astellas Pharma US INC | $24.24 | 2023 | Veozah |
| Sunovion Pharmaceuticals INC. | $19.82 | 2022 | |
| Eisai INC. | $15.78 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.38 | 2020 | |
| Endogastric Solutions, INC | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mahon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.